KKR backs monster $300M raise to build up a new-model biotech — designed by Neil Kumar and MIT’s Andrew Lo
Neil Kumar always wanted to build a different kind of biotech company at BridgeBio. And now the CEO has banked right under $300 million to continue construction work on the grand design as he thinks about growing the pipeline and starting their first marketing efforts.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 82,400+ biopharma pros reading Endpoints daily — and it's free.